Difference between revisions of "Nortriptyline-escitalopram"

From Psychiatrienet
Jump to: navigation, search
Line 10: Line 10:
 
* '''Day 1:''' simultaneously start administration of escitalopram in a normal dosage of 10 mg/day.
 
* '''Day 1:''' simultaneously start administration of escitalopram in a normal dosage of 10 mg/day.
 
| info =  
 
| info =  
* Escitalopram is a weak inhibitor of CYP2D6, which metabolizes nortriptyline.   
+
* Escitalopram is a very weak inhibitor of CYP2D6, which metabolizes nortriptyline.   
 
}}
 
}}

Revision as of 16:03, 9 March 2010

Nortriptyline
Type Antidepressant
Group TCA
links
Medscape Nortriptyline
PubChem 4543
PubMed Nortriptyline
Kompas (Dutch) Nortriptyline
Wikipedia Nortriptyline
Escitalopram
Type Antidepressant
Group SSRI
links
Medscape Escitalopram
PubChem 10832572
PubMed Escitalopram
Kompas (Dutch) Escitalopram
Wikipedia Escitalopram

Switch medication from nortriptyline to escitalopram.[1] [2]

Nietinrijdenbord.png Stop nortriptyline
  • Before day 1: gradually reduce dosage of nortriptyline to a maximum of 100 mg/day.
  • Day 1: reduce dosage of nortriptyline to 50 mg/day.
  • Day 3: reduce dosage of nortriptyline to 25 mg/day.
  • Day 8: stop administration of nortriptyline.
Eenrichtingbord.png Start escitalopram
  • Day 1: simultaneously start administration of escitalopram in a normal dosage of 10 mg/day.
Infobord.png More information
  • Escitalopram is a very weak inhibitor of CYP2D6, which metabolizes nortriptyline.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.